Skip to main content
UniHealth

Doctor search

Hong Song, MD

Diagnostic Radiology · Stanford

NPI 1205299054

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Song’s office at (650) 723-4000 to ask if they take your plan before you enroll.

California Medical Board record

Licence A151027 · Current

Licensed to practise in California · since 2017 · expires 2027-08-31 · Tulane University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$77,996

Medicare paid this office $77,996 for 1,262 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Nuclear medicine study from skull base to mid-thigh with ct scan228$23,013$97
Nuclear medicine study from skull base to mid-thigh with ct scan84$8,317$95
Nuclear medicine study whole body with ct scan73$7,199$99
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries18$5,085$282
Nuclear medicine studies of heart muscle at rest and with stress and spect65$4,393$68
See all 21 services
Every Original Medicare service billed
Nuclear medicine study from skull base to mid-thigh with ct scan228$23,013$97
Nuclear medicine study from skull base to mid-thigh with ct scan84$8,317$95
Nuclear medicine study whole body with ct scan73$7,199$99
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries18$5,085$282
Nuclear medicine studies of heart muscle at rest and with stress and spect65$4,393$68
Nuclear medicine study whole body with ct scan36$3,650$99
Dxa bone density measurement of hip, pelvis, spine301$3,172$11
Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging42$2,445$52
Radioactive drug therapy through a vein23$2,378$82
Dxa bone density measurement of hip, pelvis, spine212$2,229$11
New patient visit (60+ min)11$1,932$176
Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days18$1,539$86
Nuclear medicine study of heart muscle with metabolic evaluation and concurrent ct scan21$1,469$70
Nuclear medicine study of heart muscle at rest and with stress and spect14$802$57
Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging19$797$42
Nuclear medicine study of lung ventilation and circulation20$755$38
Nuclear medicine study of lymphatic system14$692$49
Nuclear medicine study of stomach to assess emptying13$426$33
Calculation of radiation therapy dose15$422$26
Nuclear medicine study of bone and/or joint whole body14$417$30
Piflufolastat f-18, diagnostic, 1 millicurie47$0$0

Who their Medicare patients are

1,262 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 12% · Women 65% · Also on Medicaid 19% · Health risk score 1.81. Above the middle of the specialty; the typical diagnostic radiology clinician is at 1.7.

Conditions among them: High blood pressure 68% · Cancer 37% · Diabetes 26% · Coronary heart disease 25% · Chronic kidney disease 24% · Atrial fibrillation 21% · Depression 18% · Heart failure 17% · COPD 13% · Dementia 8% · Stroke 8%.

The office billed $2,622,107, Medicare allowed $100,046 and paid $77,996; for 1,441 services of 44 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,2621,441751.81$2,622,107$77,996
20231,0721,243751.92$1,709,996$74,838
2022446479741.71$484,376$30,755

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 16 services

Original Medicare services billed in 2023
Nuclear medicine study from skull base to mid-thigh with ct scan237$24,452$98
Nuclear medicine study whole body with ct scan85$9,041$102
Nuclear medicine study from skull base to mid-thigh with ct scan93$8,980$96
Nuclear medicine studies of heart muscle at rest and with stress and spect64$4,180$65
Nuclear medicine study whole body with ct scan44$4,034$90
Radioactive drug therapy through a vein38$3,856$84
Dxa bone density measurement of hip, pelvis, spine275$2,930$11
Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging45$2,927$61
New patient visit (60+ min)15$2,448$163
Calculation of radiation therapy dose42$1,495$31
Short return visit (20+ min)14$894$60
Dxa bone density measurement of hip, pelvis, spine81$849$10
Nuclear medicine study of lymphatic system14$702$50
Nuclear medicine study of lung ventilation and circulation12$540$45
Nuclear medicine study, whole body15$494$33
Nuclear medicine study of stomach to assess emptying13$436$34

2022: 9 services

Original Medicare services billed in 2022
Nuclear medicine study from skull base to mid-thigh with ct scan105$10,870$103
Nuclear medicine study from skull base to mid-thigh with ct scan49$5,081$104
Nuclear medicine study whole body with ct scan33$3,552$104
Nuclear medicine studies of heart muscle at rest and with stress and spect37$2,503$68
Nuclear medicine study whole body with ct scan19$1,988$105
Dxa bone density measurement of hip, pelvis, spine103$1,111$11
Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging15$932$62
Nuclear medicine study of bone and/or joint whole body13$472$36
Dxa bone density measurement of hip, pelvis, spine30$318$11

Medicaid work

$23,507 in 2024

Medicaid paid $23,507 for 138 billed services this clinician did in 2024, up to 25 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh97$23,063
DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL41$444
Medicaid work by year
2024138225$23,507
2023107323$14,236
202248223$5,756
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh81$12,026
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body12$2,137
DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL14$74

2022

Largest Medicaid services in 2022
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh35$5,704
DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL13$52

Money from drug and device companies

$1,718 in 2025

Industry payments by year
2025311None$1,718
202415None$982

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Merck Sharp & DohmePrevymis$1,523
9 payments
  • Travel for Prevymis · 2025-10-20 · $135
  • Meals for Prevymis · 2025-10-09 · $60
  • Meals for Prevymis · 2025-10-09 · $55
  • Meals for Prevymis · 2025-10-09 · $65
  • Travel for Prevymis · 2025-10-08 · $162
  • Travel for Prevymis · 2025-10-08 · $283
  • Meals for Prevymis · 2025-10-08 · $150
  • Travel for Prevymis · 2025-10-08 · $142
  • Travel for Prevymis · 2025-10-08 · $473
Telix PharmaceuticalsIlluccix$169
1 payment
  • Meals for Illuccix · 2025-08-05 · $169
Azurity PharmaceuticalsAlvesco$25
1 payment
  • Meals for Alvesco · 2025-12-02 · $25
See all 11 published payments
Every published payment
Azurity PharmaceuticalsMeals · 2025-12-02Alvesco$25
Merck Sharp & DohmeTravel · 2025-10-20Prevymis$135
Merck Sharp & DohmeMeals · 2025-10-09Prevymis$60
Merck Sharp & DohmeMeals · 2025-10-09Prevymis$55
Merck Sharp & DohmeMeals · 2025-10-09Prevymis$65
Merck Sharp & DohmeTravel · 2025-10-08Prevymis$162
Merck Sharp & DohmeTravel · 2025-10-08Prevymis$283
Merck Sharp & DohmeMeals · 2025-10-08Prevymis$150
Merck Sharp & DohmeTravel · 2025-10-08Prevymis$142
Merck Sharp & DohmeTravel · 2025-10-08Prevymis$473
Telix PharmaceuticalsMeals · 2025-08-05Illuccix$169
See earlier years (2024)

2024: $982

Payments by company in 2024
Ge HealthcareNone$982
5 payments
  • Meals · 2024-10-11 · $17
  • Meals · 2024-09-11 · $82
  • Travel · 2024-06-01 · $87
  • Travel · 2024-06-01 · $165
  • Travel · 2024-06-01 · $631

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2024Their institution$363,327
Novartis Pharmaceuticals Corporation · An Open-Label, Randomized, Phase III Study Comparing 177lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) · 2025Their institution$237,374
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177lu) Vipivotide Tetraxetan Treatment in Chemo-Nave Adults With Metastatic Castration-Resistant Prostate Cancer · 2025Their institution$47,700
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Exploratory Safety and Efficacy Study With Psma, Sstr2 and Grpr Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer · 2025Their institution$29,361
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177lu]Lu-Ff58 in Patients With Selected Advanced Solid Tumors · 2024Their institution$21,924
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177lu]Lu-Ff58 in Patients With Selected Advanced Solid Tumors · 2025Their institution$8,640
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177lu) Vipivotide Tetraxetan Treatment in Chemo-Nave Adults With Metastatic Castration-Resistant Prostate Cancer · 2024Their institution$535
Novartis Pharmaceuticals Corporation · Psmaction: A Phase II/III, Open-Label, International, Multicenter, Randomized Study of Aaa817 Versus Standard of Care in the Treatment of Adult Participants With Psma Positive Metastatic Castration-Resistant Prostate Cancer Who Progressed on Or After [177 · 2025Their institution$476
Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Exploratory Safety and Efficacy Study With Psma, Sstr2 and Grpr Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer · 2024Their institution$348

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1205299054
Licence
CA A151027California A151027: Current · expires 2027-08-31
Trained
Tulane University School of Medicine, 2016
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 2085N0904X (2085N0904X); Federal specialty code 207U00000X (207U00000X); Federal specialty code 207UN0902X (207UN0902X); Diagnostic radiology (2085R0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2016-03-30
NPI last updated
2024-04-07
NPI record certified
2024-04-07

This is when the NPI record was last certified, not a medical board exam.